MedTrace Logo

Walking Football as a Supportive Medicine for Patients With Prostate Cancer

NCT04062162 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-01-13

No results posted yet for this study

Summary

Androgen deprivation therapy (ADT) is widely used in men with prostate cancer (PCa) to delay disease progression and enhance survival. The use of ADT is often associated with a vast spectrum of side effects that considerably reduce quality of life. Exercise has been proposed as a non-pharmacological strategy to counter some adverse effects of ADT among patients with PCa. Particularly, recreational football-based interventions have been suggested as an enjoyment approach to involve patients with PCa in regular exercise practice. Given its intermittent nature and vigorous efforts, adverse events associated with recreational football practice have been reported. To handle this issue and to involve patients with PCa in recreational football practice, walking football has emerged as a more suitable exercise modality

Conditions

Interventions

BEHAVIORAL

Walking football training

Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.

Sponsors & Collaborators

  • Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

    collaborator OTHER_GOV

  • University of Beira Interior

    collaborator OTHER

  • Federação Portuguesa de Futebol

    collaborator UNKNOWN

  • University Institute of Maia

    collaborator OTHER

  • Câmara Municipal de Gaia

    collaborator UNKNOWN

  • Associacao de Investigacao de Cuidados de Suporte em Oncologia

    lead OTHER

Principal Investigators

  • Andreia Capela, MD · Centro Hospitalar Vila Nova de Gaia / Espinho, EPE

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2020-05-31
Completion
2020-06-30

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04062162 on ClinicalTrials.gov